Roberto Torres
San Sebastián University(CL)Eastern Cooperative Oncology Group(US)Instituto Nacional del Cáncer(CL)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, Breast Cancer Treatment Studies, BRCA gene mutations in cancer, PARP inhibition in cancer therapy
Most-Cited Works
- → Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer(2010)630 cited
- → Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial(2013)328 cited
- → Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)(2019)146 cited
- → Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials(2017)142 cited
- → Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial(2016)125 cited
- → Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients